

Masahiro Mori

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6590894/publications.pdf>

Version: 2024-02-01

117
papers

3,689
citations

172457

29
h-index

138484

58
g-index

124
all docs

124
docs citations

124
times ranked

3320
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical features and prognosis of Miller Fisher syndrome. <i>Neurology</i> , 2001, 56, 1104-1106.	1.1	365
2	Axonal Guillain-Barré syndrome: Relation to anti-ganglioside antibodies and <i>Campylobacter jejuni</i> infection in Japan. <i>Annals of Neurology</i> , 2000, 48, 624-631.	5.3	308
3	Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1443-1452.	3.0	285
4	Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2020, 19, 298-306.	10.2	218
5	Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis. <i>Frontiers in Neurology</i> , 2018, 9, 888.	2.4	194
6	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , The, 2018, 17, 35-46.	10.2	193
7	Intravenous immunoglobulin therapy for Miller Fisher syndrome. <i>Neurology</i> , 2007, 68, 1144-1146.	1.1	128
8	Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. <i>Journal of Neurology</i> , 2009, 256, 2082-2084.	3.6	104
9	Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. <i>Journal of Neuroimmunology</i> , 2008, 196, 181-187.	2.3	102
10	Different electrophysiological profiles and treatment response in "typical" and "atypical" chronic inflammatory demyelinating polyneuropathy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 1054-1059.	1.9	95
11	Worldwide prevalence of neuromyelitis optica spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 555-556.	1.9	87
12	Cytokines and Chemokines in Neuromyelitis Optica: Pathogenetic and Therapeutic Implications. <i>Brain Pathology</i> , 2014, 24, 67-73.	4.1	79
13	Special sensory ataxia in Miller Fisher syndrome detected by postural body sway analysis. <i>Annals of Neurology</i> , 1999, 45, 533-536.	5.3	76
14	Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks. <i>Clinica Chimica Acta</i> , 2013, 421, 181-183.	1.1	74
15	Moesin is a possible target molecule for cytomegalovirus-related Guillain-Barré syndrome. <i>Neurology</i> , 2014, 83, 113-117.	1.1	56
16	Fisher syndrome: clinical features, immunopathogenesis and management. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 39-51.	2.8	55
17	Neuromyelitis optica: Concept, immunology and treatment. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 12-21.	1.5	48
18	Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: Their possible role on blood-brain barrier disruption. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1072-1084.	3.0	48

#	ARTICLE	IF	CITATIONS
19	How often and when Fisher syndrome is overlapped by Guillain-Barré syndrome or Bickerstaff brainstem encephalitis?. <i>European Journal of Neurology</i> , 2016, 23, 1058-1063.	3.3	46
20	Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 832-838.	1.9	45
21	CSF high-mobility group box 1 is associated with intrathecal inflammation and astrocytic damage in neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 517-522.	1.9	44
22	Association of anti-aquaporin-4 antibody-positive neuromyelitis optica with myasthenia gravis. <i>Journal of the Neurological Sciences</i> , 2009, 287, 105-107.	0.6	43
23	Peripheral nerve demyelination in multiple sclerosis. <i>Clinical Neurophysiology</i> , 2008, 119, 1829-1833.	1.5	42
24	Plasmapheresis and Miller Fisher syndrome: analysis of 50 consecutive cases. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002, 72, 680-680.	1.9	41
25	Serum cytokine and chemokine profiles in patients with chronic inflammatory demyelinating polyneuropathy. <i>Journal of Neuroimmunology</i> , 2015, 279, 7-10.	2.3	40
26	Association of serum levels of antibodies against MMP1, CBX1, and CBX5 with transient ischemic attack and cerebral infarction. <i>Oncotarget</i> , 2018, 9, 5600-5613.	1.8	38
27	Soluble CD40 ligand contributes to blood-brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder. <i>Journal of Neuroimmunology</i> , 2017, 305, 102-107.	2.3	35
28	IgG anti-GQ1b positive acute ataxia without ophthalmoplegia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999, 67, 668-670.	1.9	32
29	Interleukin-6 analysis of 572 consecutive CSF samples from neurological disorders: A special focus on neuromyelitis optica. <i>Clinica Chimica Acta</i> , 2017, 469, 144-149.	1.1	32
30	Epstein-Barr virus persistence and reactivation in neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 1137-1142.	1.9	31
31	Serum antinuclear antibody may be associated with less severe disease activity in neuromyelitis optica. <i>European Journal of Neurology</i> , 2016, 23, 276-281.	3.3	30
32	Novel serum autoantibodies against talin1 in multiple sclerosis: Possible pathogenetic roles of the antibodies. <i>Journal of Neuroimmunology</i> , 2015, 284, 30-36.	2.3	28
33	Current symptomatology in multiple sclerosis and neuromyelitis optica. <i>European Journal of Neurology</i> , 2015, 22, 299-304.	3.3	25
34	Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial. <i>JMIR Research Protocols</i> , 2020, 9, e17117.	1.0	23
35	Fisher Syndrome. <i>Current Treatment Options in Neurology</i> , 2011, 13, 71-78.	1.8	22
36	Concomitant chronic inflammatory demyelinating polyneuropathy and myasthenia gravis following cytomegalovirus infection. <i>Journal of the Neurological Sciences</i> , 2006, 240, 103-106.	0.6	20

#	ARTICLE	IF	CITATIONS
37	First adult case of <i>Helicobacter cinaedi</i> meningitis. <i>Journal of the Neurological Sciences</i> , 2014, 336, 263-264.	0.6	20
38	The accuracy of flow cytometric cell-based assay to detect anti-myelin oligodendrocyte glycoprotein (MOG) antibodies determining the optimal method for positivity judgement. <i>Journal of Neuroimmunology</i> , 2019, 336, 577021.	2.3	20
39	Peripheral blood helper T cell profiles and their clinical relevance in MOG-IgG-associated and AQP4-IgG-associated disorders and MS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 132-139.	1.9	20
40	Anti-MOG antibody-associated disorders: differences in clinical profiles and prognosis in Japan and Germany. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 377-383.	1.9	18
41	Novel autoantibodies against the proteasome subunit PSMA7 in amyotrophic lateral sclerosis. <i>Journal of Neuroimmunology</i> , 2018, 325, 54-60.	2.3	17
42	Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 48-55.	3.1	17
43	Recovery from optic neuritis attack in neuromyelitis optica spectrum disorder and multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2016, 367, 375-379.	0.6	16
44	Validation of the Brief International Cognitive Assessment for Multiple Sclerosis in Japan. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2017, 3, 205521731774897.	1.0	16
45	Serum anti-LRPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseases. <i>Cancer Science</i> , 2020, 111, 4453-4464.	3.9	16
46	Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration. <i>Journal of Neurology</i> , 2018, 265, 1145-1150.	3.6	15
47	Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 32-40.	1.9	15
48	Trigeminal root entry zone involvement in neuromyelitis optica and multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2015, 355, 147-149.	0.6	14
49	Risk factors for fingolimod-induced lymphopenia in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731875969.	1.0	14
50	Recombinant thrombomodulin ameliorates experimental autoimmune encephalomyelitis by suppressing high mobility group box 1 and inflammatory cytokines. <i>Clinical and Experimental Immunology</i> , 2018, 193, 47-54.	2.6	14
51	Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 72-79.	3.1	13
52	Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke. <i>BMC Medicine</i> , 2021, 19, 131.	5.5	13
53	Bickerstaff's brainstem encephalitis after an outbreak of <i>Campylobacter jejuni</i> enteritis. <i>Journal of Neuroimmunology</i> , 2008, 196, 143-146.	2.3	12
54	Detection of mumps virus RNA in cerebrospinal fluid of patients with neuromyelitis optica. <i>Neurological Sciences</i> , 2011, 32, 795-799.	1.9	11

#	ARTICLE	IF	CITATIONS
55	Intravenous immunoglobulin for maintenance treatment of multifocal motor neuropathy: A multicenter, open-label, 52-week phase 3 trial. <i>Journal of the Peripheral Nervous System</i> , 2018, 23, 115-119.	3.1	11
56	Soluble CD40 ligand disrupts the blood-brain barrier and exacerbates inflammation in experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2018, 316, 117-120.	2.3	11
57	Difference in fatigue and pain between neuromyelitis optica spectrum disorder and multiple sclerosis. <i>PLoS ONE</i> , 2020, 15, e0224419.	2.5	11
58	Novel serum autoantibodies against β -actin (ACTB) in amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 388-394.	1.7	11
59	High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis. <i>Journal of Neuroimmunology</i> , 2021, 358, 577634.	2.3	11
60	Increased levels of CSF CD59 in neuromyelitis optica and multiple sclerosis. <i>Clinica Chimica Acta</i> , 2016, 453, 131-133.	1.1	10
61	Comparison of cognitive and brain grey matter volume profiles between multiple sclerosis and neuromyelitis optica spectrum disorder. <i>PLoS ONE</i> , 2017, 12, e0184012.	2.5	10
62	Validation of the Modified Fatigue Impact Scale and the relationships among fatigue, pain and serum interleukin-6 levels in patients with neuromyelitis optica spectrum disorder. <i>Journal of the Neurological Sciences</i> , 2018, 385, 64-68.	0.6	10
63	Association of cognitive impairment with magnetic resonance imaging findings and social activities in patients with multiple sclerosis. <i>Clinical and Experimental Neuroimmunology</i> , 2014, 5, 328-335.	1.0	9
64	Seronegative neuromyelitis optica spectrum disorder patients diagnosed using new diagnostic criteria. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1371-1375.	3.0	9
65	Nodopathy: chronic inflammatory demyelinating polyneuropathy with anti-neurofascin 155 antibodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 459-459.	1.9	9
66	Role of interleukin-6 in the pathogenesis of neuromyelitis optica. <i>Clinical and Experimental Neuroimmunology</i> , 2013, 4, 167-172.	1.0	8
67	Urinary symptoms and neurological disabilities are differentially correlated between multiple sclerosis and neuromyelitis optica. <i>Clinical and Experimental Neuroimmunology</i> , 2016, 7, 52-58.	1.0	8
68	Relapse numbers and earlier intervention by disease modifying drugs are related with progression of less brain atrophy in patients with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2019, 403, 78-84.	0.6	8
69	Seroconversion of anti-aquaporin-4 antibody in NMO spectrum disorder: a case report. <i>Journal of Neurology</i> , 2012, 259, 980-981.	3.6	6
70	Chronic inflammatory demyelinating polyneuropathy: The spectrum and immunopathogenesis deciphered by electrophysiology and neuroimaging. <i>Clinical and Experimental Neuroimmunology</i> , 2018, 9, 47-53.	1.0	6
71	Peroxiredoxins are involved in the pathogenesis of multiple sclerosis and neuromyelitis optica spectrum disorder. <i>Clinical and Experimental Immunology</i> , 2020, 202, 239-248.	2.6	6
72	Serum Sphingosine 1-Phosphate (S1P): A Novel Diagnostic Biomarker in Early Acute Ischemic Stroke. <i>Frontiers in Neurology</i> , 2020, 11, 985.	2.4	6

#	ARTICLE	IF	CITATIONS
73	AQP4-IgG autoimmunity in Japan and Germany: Differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110068.	1.0	6
74	A patient with neuromyelitis optica with positive anti-Ro (SS-A) antibody presenting with intractable hiccup and nausea. <i>Modern Rheumatology</i> , 2011, 21, 561-562.	1.8	5
75	Is "Bickerstaff brainstem encephalitis" really encephalitis?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 712-712.	1.9	5
76	Are more sphingosine 1-phosphate receptor agonists a better therapeutic option against multiple sclerosis?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 1180-1180.	1.9	5
77	Lower motor neuron syndrome associated with IgG anti-GM1 antibodies revisited. <i>Journal of Neuroimmunology</i> , 2014, 272, 62-66.	2.3	5
78	Steroid-Responsive Epilepsia Partialis Continua with Anti-Thyroid Antibodies: A Spectrum of Hashimoto's Encephalopathy. <i>Case Reports in Neurology</i> , 2014, 6, 166-170.	0.7	5
79	Validation of the Japanese version of the Modified Fatigue Impact Scale and assessment of the effect of pain on scale responses in patients with multiple sclerosis. <i>Clinical and Experimental Neuroimmunology</i> , 2015, 6, 409-412.	1.0	5
80	Autoantibodies against vinculin in patients with chronic inflammatory demyelinating polyneuropathy. <i>Journal of Neuroimmunology</i> , 2015, 287, 9-15.	2.3	5
81	Serum soluble Talin-1 levels are elevated in patients with multiple sclerosis, reflecting its disease activity. <i>Journal of Neuroimmunology</i> , 2017, 305, 131-134.	2.3	5
82	Identification of Serum Anti-GADD34 Antibody as a Common Marker of Diabetes Mellitus and Parkinson Disease. , 2017, 07, .		5
83	Cognitive Impairment in Multiple System Atrophy Is Related to White Matter Damage Detected by the T1-Weighted/T2-Weighted Ratio. <i>European Neurology</i> , 2021, 84, 435-443.	1.4	5
84	Benign neuromyelitis optica is rare in Japanese patients. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1204-1208.	3.0	4
85	MOG antibody disorders and AQP4 antibody NMO spectrum disorders share a common immunopathogenesis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 900-900.	1.9	4
86	Atypical chronic inflammatory demyelinating polyneuropathies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 121-121.	1.9	4
87	Serum anti-John Cunningham virus antibody seroprevalence and index among Japanese patients with neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2020, 26, 128-129.	3.0	4
88	Comparison of brain atrophy in patients with multiple sclerosis treated with first- versus second-generation disease modifying therapy without clinical relapse. <i>European Journal of Neurology</i> , 2020, 27, 2056-2061.	3.3	4
89	Cultural bias in motor function patterns: Potential relevance for predictive, preventive, and personalized medicine. <i>EPMA Journal</i> , 2021, 12, 91-101.	6.1	4
90	Complete Relief of Painful Tonic Seizures in Neuromyelitis Optica Spectrum Disorder by Satralizumab Treatment. <i>Internal Medicine</i> , 2022, 61, 2785-2787.	0.7	4

#	ARTICLE	IF	CITATIONS
91	Change in vital signs after fingolimod initiation in patients with multiple sclerosis: the possible need for 24 h monitoring. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 607-608.	2.4	3
92	Paranodal destruction and axo-glial dysjunction in a subtype of CIDP with anticontaction-1 antibodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 707-707.	1.9	3
93	Serum cytokine and chemokine profiles in patients with juvenile muscular atrophy of distal upper extremity (Hirayama disease). <i>Journal of Neuroimmunology</i> , 2017, 302, 20-22.	2.3	3
94	Different patterns of brainstem and cerebellar MRI abnormalities in demyelinating disorders with MOG and aquaporin-4 antibodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 348-348.	1.9	3
95	Dementia and Parkinson-like syndrome with basal ganglia lesion in neuromyelitis optica spectrum disorders. <i>Neurocase</i> , 2021, 27, 223-226.	0.6	3
96	A case of fulminant neuromyelitis optica presenting with destructive lesions in whole-brain. <i>Clinical Neurology and Neurosurgery</i> , 2014, 116, 87-89.	1.4	2
97	Efficacy and safety of dimethyl fumarate in treatment-naïve Japanese patients with multiple sclerosis: Interim analysis of the randomized placebo-controlled study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731985272.	1.0	2
98	Cryptococcal Meningitis in a Fingolimod-Treated Patient. <i>Neurology: Clinical Practice</i> , 2021, 11, e549-e550.	1.6	2
99	Upbeat nystagmus at caudal brainstem lesions in four cases with multiple sclerosis and its related disorders. <i>Clinical and Experimental Neuroimmunology</i> , 2013, 4, 206-209.	1.0	1
100	Autoimmune polyendocrine syndrome type 3 in a multiple sclerosis patient. <i>Clinical and Experimental Neuroimmunology</i> , 2015, 6, 299-303.	1.0	1
101	Anatomical connectivity elucidated by analysing thalamic atrophy in neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1075-1075.	1.9	1
102	Cognition with magnetic resonance imaging findings and social activities in patients with multiple sclerosis in a Japanese cohort. <i>Clinical and Experimental Neuroimmunology</i> , 2019, 10, 41-48.	1.0	1
103	Clinical difference after the first optic neuritis between aquaporin-4-IgG-associated and myelin oligodendrocyte glycoprotein-IgG-associated disorders. <i>Journal of Neurology</i> , 2021, , 1.	3.6	1
104	Remyelination and neuroprotective effects of alemtuzumab therapy in patients with multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1251-1251.	1.9	1
105	Correlation of the symbol digit modalities test with the quality of life and depression in Japanese patients with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103427.	2.0	1
106	Low anti-CFL1 antibody with high anti-ACTB antibody is a poor prognostic factor in esophageal squamous cell carcinoma. <i>Esophagus</i> , 2022, 19, 617-625.	1.9	1
107	Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines: The risks and benefits. <i>Clinical and Experimental Neuroimmunology</i> , 2013, 4, 249-250.	1.0	0
108	Environment surrounding the ganglioside clusters as immunological targets in Guillain-Barré syndrome. <i>Clinical and Experimental Neuroimmunology</i> , 2013, 4, 10-11.	1.0	0

#	ARTICLE	IF	CITATIONS
109	Multiple enhancing brain lesions after discontinuation of fingolimod in a patient with multiple sclerosis. <i>Clinical and Experimental Neuroimmunology</i> , 2014, 5, 52-53.	1.0	0
110	A Case of Anti-aquaporin-4 Antibody-Seronegative NMO Spectrum Disorder with Balb ³ Concentric Lesions. <i>Internal Medicine</i> , 2014, 53, 531-531.	0.7	0
111	The role of granulocyte-macrophage colony-stimulating factor in the pathogenesis of neuromyelitis optica: A white or black knight?. <i>Clinical and Experimental Neuroimmunology</i> , 2015, 6, 70-77.	1.0	0
112	Moesin, membrane-organizing extension spike protein, is a possible immunological target in Guillain-Barré syndrome after cytomegalovirus infection. <i>Clinical and Experimental Neuroimmunology</i> , 2015, 6, 5-6.	1.0	0
113	Geographical differences in preventative therapies for neuromyelitis optica spectrum disorder. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 620-620.	1.9	0
114	Insights from the differences in clinical profiles of neuroimmune disorders between patients in Japan and those in Western countries. <i>Clinical and Experimental Neuroimmunology</i> , 2021, 12, 146-147.	1.0	0
115	Methodology for identification of new target molecules in neuroimmunological disorders. <i>Clinical and Experimental Neuroimmunology</i> , 2021, 12, 202-207.	1.0	0
116	Severe orthostatic hypotension associated with lesions of the area postrema in neuromyelitis optica spectrum disorder. <i>ENeurologicalSci</i> , 2021, 23, 100335.	1.3	0
117	Cell-based flow cytometry assay for simultaneous detection of multiple autoantibodies in a single serum sample. <i>Analytical Biochemistry</i> , 2022, , 114721.	2.4	0